Leqvio vs Losartan: Cost and Access Head-to-Head

Why These Two Drugs Get Compared

Patients searching "Leqvio vs Losartan" are often managing multiple cardiometabolic risk factors at once and want to understand which medication delivers greater value. The comparison, however, is not apples to apples. Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences hepatic PCSK9 production, resulting in sustained LDL cholesterol reduction with just two injections per year after an initial loading dose 1. Losartan is an angiotensin II receptor blocker (ARB) prescribed primarily for hypertension, diabetic nephropathy, and stroke risk reduction in patients with left ventricular hypertrophy 2.

These drugs act on entirely separate pathways. One lowers LDL-C. The other lowers blood pressure. A patient with both hyperlipidemia and hypertension may end up on both medications simultaneously, not choosing between them. The real comparison becomes relevant when patients are evaluating cost, coverage hurdles, and practical access for each therapy within a broader cardiometabolic treatment plan.

Mechanism of Action: Two Distinct Pathways

Leqvio works by targeting messenger RNA for PCSK9 inside hepatocytes. By silencing PCSK9 production, the drug allows more LDL receptors to remain on the liver cell surface, pulling LDL cholesterol from the bloodstream. The effect persists for roughly six months per injection because siRNA remains active within hepatocytes long after administration 1. This mechanism is entirely independent of statin therapy, which is why inclisiran is typically prescribed as an add-on for patients who cannot reach LDL targets on statins alone.

Losartan blocks the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding, the drug relaxes vascular smooth muscle, reduces aldosterone secretion, and lowers systemic blood pressure. The LIFE trial demonstrated that losartan's cardiovascular benefits extended beyond blood pressure control alone, showing a 25% relative risk reduction in stroke compared with atenolol despite similar blood pressure lowering 2. Losartan also has a modest uricosuric effect, lowering serum uric acid, a property unique among ARBs.

These mechanisms do not overlap. Switching from one to the other would leave either high LDL or high blood pressure untreated.

Clinical Evidence Compared

The key evidence for Leqvio comes from the pooled ORION-10 and ORION-11 trials, published in the New England Journal of Medicine in 2020 1. ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) in the United States. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents across Europe and South Africa. Both trials randomized patients to inclisiran 284 mg or placebo, administered subcutaneously at day 1, day 90, and every six months thereafter, on top of maximally tolerated statin therapy.

Results were consistent across both studies. At day 510, inclisiran reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 compared with placebo (P<0.001 for both). Time-averaged reductions over the full study period were 53.8% and 49.2%, respectively. Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo, but most were mild. Discontinuation rates were low.

For Losartan, the landmark LIFE trial (Lancet, 2002) enrolled 9,193 patients aged 55 to 80 with hypertension and electrocardiographic evidence of left ventricular hypertrophy 2. Patients were randomized to losartan-based or atenolol-based therapy for a mean of 4.8 years. The primary composite endpoint (cardiovascular death, stroke, or myocardial infarction) occurred in 11% of the losartan group versus 13% of the atenolol group, a 13% adjusted relative risk reduction (P = 0.021). The stroke reduction was even more pronounced at 25%.

No trial has ever randomized patients to inclisiran versus losartan because the clinical question does not make pharmacological sense. Any comparison must be indirect and should focus on how each drug fits within a patient's overall cardiometabolic regimen rather than positioning them as alternatives.

Cost Breakdown: List Price, Out-of-Pocket, and Real-World Spend

The cost gap between these two medications is enormous. Leqvio carries a wholesale acquisition cost (WAC) of approximately $6,500 per injection. The recommended dosing schedule is three injections in year one (day 1, day 90, day 270) followed by two injections per year thereafter. That translates to roughly $19 to 500 in year one and $13,000 annually from year two onward before insurance, copay assistance, or rebates.

Losartan costs almost nothing by comparison. Generic losartan potassium (25 mg, 50 mg, or 100 mg tablets) is available at most U.S. pharmacies for $4 to $15 per month through discount programs and generic formulary pricing. Even without insurance, a 90-day supply rarely exceeds $30. Annual out-of-pocket cost for an uninsured patient on losartan is typically under $180.

For insured patients, the picture shifts but the disparity remains. Most commercial plans cover losartan at Tier 1 with a copay of $0 to $10. Medicare Part D plans also cover losartan with minimal cost sharing. Leqvio, classified as a Part B "buy-and-bill" drug when administered in a physician's office, is covered under Medicare Part B rather than Part D. Medicare Part B covers 80% of the allowable amount after the annual deductible, leaving the patient responsible for approximately $1,300 per injection unless supplemental insurance or Medigap covers the remainder.

Novartis offers the Leqvio Complete patient support program, which includes copay cards for commercially insured patients (potentially reducing out-of-pocket cost to $0 per injection) and assistance navigating prior authorization. Patients on government insurance programs (Medicare, Medicaid, Tricare) are not eligible for commercial copay cards, though the Medicare Part B structure and supplemental coverage may still reduce costs significantly.

Dr. Seth Baum, president of the American Society for Preventive Cardiology, has noted: "The challenge with novel lipid-lowering therapies is not whether they work. The challenge is making sure cost does not become the reason a patient with ASCVD fails to reach their LDL target."

Insurance Coverage and Prior Authorization

Losartan faces essentially no insurance barriers. It is a Tier 1 generic on virtually every commercial, Medicare Part D, and Medicaid formulary in the United States 3. No prior authorization is required. No step therapy applies. A prescriber writes a prescription; the pharmacy fills it.

Leqvio's coverage pathway is more complex. Because it is a physician-administered injectable, it typically falls under the medical benefit (not pharmacy benefit) for commercial plans and under Part B for Medicare. Coverage requirements vary by payer but commonly include 4:

Prior authorization is the norm. Most payers require documentation that the patient has ASCVD or familial hypercholesterolemia (FH), has been on maximally tolerated statin therapy for at least 90 days, and still has LDL-C above goal (typically above 70 mg/dL for ASCVD or above 100 mg/dL for primary prevention FH). Some commercial plans also require a trial or intolerance documentation for ezetimibe before approving inclisiran.

Step therapy requirements vary. Certain plans require documentation of PCSK9 monoclonal antibody (evolocumab or alirocumab) trial or intolerance before covering inclisiran, though this is becoming less common as payers recognize inclisiran's differentiated dosing advantage.

Buy-and-bill logistics add another layer. The prescribing physician's office must purchase the drug, administer it, and then bill the payer for reimbursement. Practices unfamiliar with this workflow or concerned about reimbursement risk may hesitate to stock Leqvio, creating access bottlenecks that have nothing to do with the drug's clinical profile.

According to data from the IQVIA Institute, specialty medication access programs like Leqvio Complete can reduce time-to-therapy by 40% to 60% compared with patients navigating insurance alone, but this still means days to weeks of delay versus same-day access for losartan.

Who Is a Candidate for Each Drug

The patient populations for these two drugs overlap significantly in terms of overall cardiometabolic risk, but the specific indications are different.

Leqvio is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for adults with ASCVD or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering 4. The typical candidate has already tried high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) with or without ezetimibe and still has LDL-C above guideline targets. A patient who cannot tolerate statins at any dose may also be a candidate, though inclisiran as monotherapy produces somewhat lower absolute LDL reductions.

Losartan is approved for hypertension, diabetic nephropathy in type 2 diabetes with elevated serum creatinine and proteinuria, and stroke risk reduction in patients with hypertension and left ventricular hypertrophy 3. It is a first-line antihypertensive option in guidelines from the American College of Cardiology and American Heart Association, particularly for patients with comorbid diabetes, chronic kidney disease, or heart failure with reduced ejection fraction 5.

Many patients with ASCVD also have hypertension. A 62-year-old with a prior MI, LDL-C of 85 mg/dL on rosuvastatin 40 mg plus ezetimibe, and blood pressure of 148/92 mmHg might appropriately receive both Leqvio (to push LDL below 70) and losartan (to control blood pressure and provide renal protection). These medications complement each other.

Adherence and Convenience

Medication adherence is a major differentiator. Losartan requires daily oral dosing. Large epidemiological studies show that adherence to daily antihypertensive medication drops below 50% within 12 months of initiation 6. Missed doses lead to blood pressure variability, which independently increases stroke risk.

Leqvio's twice-yearly dosing (after the loading phase) effectively eliminates the adherence problem for LDL-C management. The patient shows up for an office visit, receives the injection, and achieves sustained LDL lowering until the next visit. In ORION-10 and ORION-11, adherence to the injection schedule exceeded 95% 1. This is a meaningful advantage for patients who struggle with daily pill burdens.

The tradeoff is flexibility. A patient on losartan can stop, adjust, or restart therapy independently. A patient who receives a Leqvio injection cannot "un-inject" the medication if side effects emerge. The siRNA will continue suppressing PCSK9 for approximately six months regardless. In practice, serious adverse events with inclisiran have been rare, but the irreversibility of each dose is worth discussing with patients before administration.

Dr. Karol Watson, professor of medicine and cardiology at UCLA, has stated: "When a patient only needs to come in twice a year for a therapy that cuts their LDL in half, we remove one of the biggest barriers in cardiovascular prevention. But that convenience comes at a price point that the system has not fully figured out how to absorb."

Side Effects and Safety Profile

Losartan's safety profile is well-established over three decades of clinical use. Common side effects include dizziness, upper respiratory infection, nasal congestion, and back pain. The most clinically significant risks are hyperkalemia (especially when combined with potassium-sparing diuretics or in patients with chronic kidney disease), acute kidney injury in volume-depleted patients, and angioedema (rare, but more common in patients with prior ACE inhibitor angioedema). Losartan is absolutely contraindicated in pregnancy due to fetal toxicity 3.

Leqvio's safety data, while more limited in duration, has been reassuring. Across the ORION program, the most common adverse event was injection-site reaction (5% vs 0.7% placebo), typically mild erythema or pain resolving within one to two days 1. Bronchitis and urinary tract infections occurred slightly more frequently in the inclisiran group, though no causal mechanism has been established. Liver transaminase elevations were not significantly different from placebo. No cases of myopathy or rhabdomyolysis (concerns with statin therapy) have been attributed to inclisiran.

Long-term cardiovascular outcomes data for inclisiran are pending from the ORION-4 trial, a 15,000-patient event-driven study expected to report in 2026. Until those results are available, inclisiran's cardiovascular benefit is inferred from the well-established relationship between LDL-C lowering and reduced ASCVD events, supported by Mendelian randomization studies showing that lifelong PCSK9 inhibition reduces coronary heart disease risk by approximately 19% per mmol/L of LDL-C reduction 7.

Practical Access: Pharmacy vs. Clinic

A patient prescribed losartan walks into any retail pharmacy and picks up a bottle of tablets. Generic availability at over 60 to 000 U.S. pharmacy locations means access is functionally universal. Mail-order pharmacies offer 90-day supplies at even lower prices. No cold chain, no special storage.

A patient prescribed Leqvio must receive the injection in a healthcare provider's office, infusion center, or, in some cases, a specialty pharmacy with injection capabilities. The drug requires refrigerated storage (2°C to 8°C) and must be administered by a healthcare professional. This means the patient needs a scheduled appointment, a willing provider who stocks the drug or can obtain it through specialty distribution, and insurance verification completed before the visit.

Some practices have been slow to adopt buy-and-bill for Leqvio due to reimbursement uncertainty or upfront drug acquisition costs. Larger health systems and cardiology groups with established infusion operations have integrated Leqvio more readily. For patients in rural areas or those without access to a cardiologist comfortable with the buy-and-bill model, the drug may be practically unavailable even if insurance covers it.

The Bottom Line for Cardiometabolic Patients

Comparing Leqvio and losartan on cost and access alone tells a clear story: losartan is one of the most affordable and accessible medications in all of cardiovascular medicine, while Leqvio is a high-cost specialty therapy with significant insurance and logistical requirements. But this comparison misses the point if it leads a patient to think they must choose one over the other. These drugs treat different diseases through different mechanisms. A patient who needs LDL lowering will not achieve that with losartan. A patient who needs blood pressure control will not achieve that with inclisiran.

The 2018 ACC/AHA cholesterol guidelines recommend adding non-statin therapies (including PCSK9-targeted agents) for patients with ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy 8. For those patients, the relevant cost question is not "Leqvio or losartan" but "can I access and afford Leqvio in addition to the losartan and statin I already take?"

Patients who face cost barriers to Leqvio should ask their prescriber about the Leqvio Complete program, Novartis patient assistance for uninsured or underinsured patients, and whether their clinic can initiate the prior authorization and benefits verification process before scheduling the first injection appointment. For losartan, programs like GoodRx, Mark Cuban Cost Plus Drug Company, and $4 generic lists at major pharmacy chains keep out-of-pocket costs minimal regardless of insurance status.